<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3210">
  <stage>Registered</stage>
  <submitdate>27/06/2011</submitdate>
  <approvaldate>27/06/2011</approvaldate>
  <nctid>NCT01383720</nctid>
  <trial_identification>
    <studytitle>REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve SystEm</studytitle>
    <scientifictitle>REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve SystEm</scientifictitle>
    <utrn />
    <trialacronym>REPRISE I</trialacronym>
    <secondaryid>TP3659</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Aortic Valve Stenosis</healthcondition>
    <healthcondition>Aortic Valve Calcification</healthcondition>
    <healthcondition>Aortic Valve Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Lotus Valve System

Experimental: Lotus Valve System - Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis


Treatment: devices: Lotus Valve System
The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical Procedural Success - Clinical procedural success defined as successful implantation of a Lotus Valve System (Device Success) without in-hospital Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) through discharge or 7 days post-procedure, whichever comes first.</outcome>
      <timepoint>Discharge or 7 days post-procedure, whichever comes first</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Device Performance Endpoint-Repositioning - Successful repositioning of the Lotus Valve System if repositioning is attempted</outcome>
      <timepoint>procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Device Performance Endpoint-Valve Retrieval, if Attempted - Successful retrieval of the Lotus Valve System if retrieval is attempted</outcome>
      <timepoint>procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Central Aortic Regurgitation - As determined by echocardiography</outcome>
      <timepoint>Discharge or 7 days post-procedure, whichever comes first</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Paravalvular Aortic Regurgitation - As determined by echocardiography</outcome>
      <timepoint>Discharge or 7 days post-procedure, whichever comes first</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patient must be at least 70 years of age or older, and meets all of the criteria
             below.

          2. Patient has documented calcified native aortic valve stenosis, defined with an initial
             aortic valve area (AVA) of &lt;1.0 cm2 (or AVA index of &lt;0.6 cm2/m2), and a mean pressure
             gradient &gt;40 mmHg or a jet velocity &gt;4 m/s, as measured by echocardiography.

          3. The patient is considered at high risk for surgical aortic valve replacement with an
             STS (Society of Thoracic Surgeons) score =8% or a EuroSCORE =20%, or documented
             multidisciplinary heart team agreement that the patient is at high risk for surgery
             due to frailty and/or coexisting comorbidities.

          4. Symptomatic aortic valve stenosis with New York Heart Association (NYHA) Functional
             Class = II.

          5. Patient has a documented aortic annulus size between 19 and 22 mm (able to accommodate
             the 23 mm Lotus Valve). Pre-procedure measurement by transthoracic echocardiography
             (TTE) is required. Other imaging modalities (e.g., transesophageal echocardiography
             (TEE), CT scan) can be used in an adjunctive manner.

          6. Patient (or legal representative) understands the trial requirements and the treatment
             procedures, and provides written informed consent.

          7. Patient agrees and is capable of returning to the study hospital for all required
             scheduled follow up visits.</inclusivecriteria>
    <inclusiveminage>70</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patient has a congenital unicuspid or bicuspid aortic valve.

          2. Patient with an acute myocardial infarction (MI) within 30 days of the index procedure
             (defined as Q wave MI, or non-Q wave MI with total creatine kinase (CK) elevation =
             twice normal in the presence of CK-MB elevation and/or troponin level elevation (WHO
             definition)).

          3. Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA)
             within the past 6 months, or has any permanent neurologic defect prior to study
             enrollment.

          4. Patient is on dialysis or has serum creatinine level &gt;3.0 mg/dL.

          5. Patient has a pre-existing prosthetic heart valve (aortic or mitral) or a prosthetic
             ring in any position.

          6. Patient has &gt;2+ mitral regurgitation or &gt;2+ aortic regurgitation (ie., patient cannot
             have more than moderate mitral or aortic regurgitation).

          7. Moderate to severe pulmonary hypertension (PA systolic pressure &gt;60 mm Hg) as assessed
             by transthoracic echocardiography.

          8. Patient has a need for emergency surgery for any reason.

          9. Patient has a history of endocarditis within 12 months of index procedure or evidence
             of an active systemic infection or sepsis.

         10. Patient has echocardiographic evidence of intra-cardiac mass, thrombus or vegetation.

         11. Patient has Hgb &lt;9 g/dL, platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3, and
             white blood cell (WBC) count &lt;3,000 cells/mm3.

         12. Patient is receiving chronic (=72 hours) anticoagulation therapy (e.g., heparin,
             warfarin) and who cannot tolerate concomitant therapy with aspirin and clopidogrel
             (patients who require chronic anticoagulation must be treated with either aspirin or
             clopidogrel).

         13. Patient has active peptic ulcer disease, gastrointestinal (GI) bleed within the past 3
             months, other bleeding diathesis or coagulopathy or will refuse transfusions.

         14. Patient is contraindicated for transesophageal echocardiography (TEE).

         15. Patient has known hypersensitivity to contrast agents that cannot be adequately
             pre-medicated, or has known hypersensitivity to aspirin, all thienopyridines, heparin,
             nickel, titanium, or polyurethanes.

         16. Patient has a life expectancy of less than 12 months due to non-cardiac, co-morbid
             conditions based on the assessment of the investigator at the time of enrollment.

         17. Patient has other cardiac devices or hardware with which the study device will
             interfere with device placement (per physician judgment).

         18. Patient has hypertrophic obstructive cardiomyopathy.

         19. Patient has any therapeutic invasive cardiac procedure within 30 days prior to the
             index procedure.

         20. Untreated clinically significant coronary artery disease requiring revascularization.

         21. Patient has documented left ventricular ejection fraction (LVEF) &lt;30%.

         22. Patient is in cardiogenic shock or has hemodynamic instability requiring inotropic
             support or mechanical support devices.

         23. Patient has severe peripheral vascular disease (including aneurysm defined as maximal
             luminal diameter &gt;5cm or with documented presence of thrombus, marked tortuosity,
             narrowing of the abdominal aorta, severe unfolding of the thoracic aorta or thick
             (&gt;5mm), protruding or ulcerated atheroma in the aortic arch) or symptomatic carotid or
             vertebral disease.

         24. Patient has a femoral artery lumen of &lt;6.0 mm or severe iliofemoral tortuosity or
             calcification that would prevent safe placement of the introducer sheath.

         25. Current problems with substance abuse (e.g. alcohol, cocaine, heroin, etc).

         26. Patient is participating in another investigational drug or device study that has not
             reached its primary endpoint.

         27. Patient has preexisting untreated conduction system disorders: Type II second-degree
             atrioventricular (AV) block, bifascicular or trifascicular block.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>11</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>9/05/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>St. Vincent's Hospital - Melbourne</hospital>
    <hospital>Southern Health Monash Medical Centre - Melbourne</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3040 - Melbourne</postcode>
    <postcode>3168 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boston Scientific Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a prospective, single-arm feasibility study designed to assess the acute safety and
      performance of the Lotus Valve System for transcatheter aortic valve replacement in
      symptomatic patients with calcified aortic valve stenosis and who are at high risk for
      surgical intervention.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01383720</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ian Meredith, MBBS, PhD</name>
      <address>Southern Health, Monash Medical Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>